Adult C57BL/10 mice 
The retrovirus-induced human acquired immunodeficiency syndrome (AIDS) has been regarded as an incurable disease so far. Although a number of efforts in the identification, isolation, and characterization of human immunodeficiency virus (HIV) have been successfully carried out, relatively little is known about the pathogenesis of AIDS. Since nonhuman primates infected with HIV do not develop the immunodeficiency syndrome seen in humans, there have been many difficulties in investigating the pathogenesis of AIDS as well as in evaluating anti-HIV drugs by using animal models.
The LP-BM5 murine leukemia virus (MuLV) originally isolated by Laterjet and Duplan (8) causes a syndrome, termed murine AIDS (MAIDS), characterized by hypergammaglobulinemia, lymphadenopathy, severe immunodeficiency, enhanced susceptibility to infection, and the development of B-cell lymphomas in adult mice of susceptible strains (2, 3, 5, 6, 11, 12, 15, 24) . One of the unique features of LP-BM5 MuLV is that it induces a persistent immunosuppression not only in newborn mice but also in adult mice. Since many features of this syndrome are common to those defined in human AIDS, as described above, MAIDS may serve as a useful experimental model for understanding the pathogenesis of AIDS as well as searching for anti-HIV drugs. In another study with the MAIDS system, we demonstrated that antigen-presenting cells (APCs) from LP-BM5 MuLV-infected mice failed to stimulate the proliferation of * Corresponding author.
antigen-specific helper T-cell clones (lOa). This result may explain why functional abnormalities of CD4+ helper T cells are observed before the numbers of these cells decline (1, 7) and supports the notion that APCs are one of the initial targets for HIV infections in humans. The present study was undertaken to establish an experimental system for screening antiretrovirus drugs in vivo with MAIDS.
MATERIALS AND METHODS Mice. Male C57BL/10 mice (BlO mice) were used at 4 weeks of age. Mice were purchased from Japan SLC Inc., Shizuoka, Japan. The body weight of each mouse was checked on the day of LP-BM5 MuLV inoculation and on the day of sacrifice. Both B6.C-H-2bml and B6.C-H-2bm12 mice were originally purchased from Jackson Laboratory, Bar Harbor, Maine, and then bred in our own animal colony. All the mice were specific pathogen free and were housed in an air-conditioned room. water consumption, we estimated that this concentration provided a dose of approximately 250 mg/kg per day.
RESULTS
Immunodeficiency induced in B10 mice by LP-BMS MuLV inoculation. For the rapid evaluation of antiviral effects of test drugs, it would be advantageous to use viruses that are able to induce a rapid and severe immunodeficiency in host experimental mice. In the first experiment, we examined the effect of LP-BM5 MuLV inoculation on the proliferative responses of spleen cells from B10 mice against alloantigens or mitogens. Spleen cells from untreated B10 mice or B10 mice intraperitoneally inoculated with LP-BM5 MuLV were stimulated in vitro with class I alloantigens (B6.C-H-2bml), class II alloantigens (B6.C-H-2bml2), or mitogens (ConA or LPS). Three to four days later, the cultures were assayed for their proliferative responses by measurement of [3HJthy-midine incorporation. Both allogeneic responses and mitogenic responses were found to be significantly depressed 3 weeks after LP-BM5 MuLV inoculation and severely depressed 5 weeks after LP-BM5 MuLV inoculation (Table 1) .
Since the number of splenic T cells was not reduced in B10 mice during this early period of virus infection (data not shown), it was likely that the qualitative rather than the quantitative defect in T cells was responsible for the abovedescribed results. Alternatively, the APC activity might have been affected in LP-BM5 MuLV-inoculated B10 mice, because the effective interaction between T cells and APCs is crucial for T-cell recognition of antigens as well as mitogens (21) . Irradiated (3,000 rads) spleen cells from untreated or LP-BM5 MuLV-inoculated B10 mice were used 2) , and the average number of spleen cells was also significantly increased. When B10 mice were continuously treated with AZT from 3 days before LP-BM5 MuLV inoculation, the magnitude of splenomegaly was markedly reduced (Tables 3 and 4 , groups 3 and 4). In untreated animals, both the mitogenic response and the APC activity of spleen cells in B10 mice inoculated with LP-BM5 MuLV were almost completely abrogated (Tables 3 and 4 , group 2). The administration of AZT reconstituted both activities (Tables 3 and 4, groups 3 and 4) , as expected, indicating that the AZT treatment had a prophylactic effect on the induction of immunodeficiency caused by LP-BM5 MuLV infection. The average body weight of the mice was comparable in the experimental groups, indicating that the short duration (5 weeks) of AZT treatment did not adversely affect body weight.
Therapeutic effect of AZT on the immunodeficiency caused by LP-BM5 MuLV inoculation in B10 mice. B10 mice were inoculated with LP-BM5 MuLV, and AZT treatment was started simultaneously or 8 or 15 days later (Tables 5 and 6, groups 3, 4, and 5). AZT treatment started at the same time as LP-BM5 MuLV inoculation completely prevented the induction of immunosuppression in mice (Tables 5 and 6 , group 2 versus group 3). On the other hand, the longer the initiation of AZT administration was delayed, the less effective was the treatment for the immunodeficiency caused by LP-BM5 MuLV inoculation in B10 mice (Tables 5 and 6 (Tables 5 and 6 , group 1 versus group 2). This kind of elevation in the IgG level in the serum of LP-BM5 MuLV-infected B10 mice has also been reported by others (6) . The IgG level in the serum of B10 mice treated with AZT beginning at LP-BM5 MuLV inoculation stayed within the normal range (Tables 5 and 6 , group 3), but a delay in starting AZT administration reduced the effect of AZT on the hypergammaglobulinemia.
Serum from B10 mice infected with LP-BM5 MuLV showed about eightfold higher RT activity than did that of control B10 mice, indicating that viremia was already present in B10 mice 5 weeks after LP-BM5 MuLV inoculation. The administration of AZT markedly reduced RT activity in serum from B10 mice inoculated with LP-BM5 MuLV. Even when the AZT treatment was started 2 weeks after LP-BM5 MuLV inoculation, the RT activity in serum was no higher than that in control mice (Tables 5 and 6,   TABLE 4 . Statistical analyses of the data reported in (Tables 5 and 6 ). We assume that once the immunodeficiency was triggered by the virus infection, it persisted regardless of whether viruses continuously existed.
A number of studies have used murine models for antiretroviral therapy as well as prophylaxis (17) (18) (19) (20) . Most of them, however, used MuLVs which had very short latent periods and which therefore rapidly induced leukemia rather than immunodeficiency. The LP-BM5 MuLV used in the present study was able to induce an immunodeficiency which might not have been caused by tumor development or by an immunosuppressive component derived from retroviral envelope protein pl5E (22) . Although little is known about the induction mechanisms for LP-BM5 MuLV-induced immunodeficiency, this MAIDS system may allow rapid and inexpensive screening for antiretrovirus agents that would be also effective for human AIDS.
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